Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    20124187 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
Conditions: Breast Neoplasms;   HER2/Neu Positive;   Geriatric Health Services
Interventions: Drug: Lapatinib;   Drug: Trastuzumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
2 Recruiting Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Trastuzumab

Study has passed its completion date and status has not been verified in more than two years.